Co-Founder and Managing Director, AllosterX
Cynthia is a Managing Director of AllosteRx Capital, an early-stage venture capital firm she co-founded in 2018. AllosteRx invests in the wealth of life sciences opportunities originating from “under-ventured” regions and institutions.
As a seasoned investment professional with fifteen years’ experience in venture capital, Cynthia has successfully sourced investments, secured financings, negotiated terms, and provided leadership through partnerships, public listings and M&A. Her experience includes creating companies de novo and leading investments into companies developing therapeutics, devices and diagnostic tools. Cynthia has taken active roles, including chair, on boards of companies located in Canada and the US from start-up to revenue-generating stages. These include Acer Therapeutics (NASDAQ: ACER), Cytochroma (acquired by OPKO Health), VisualSonics (acquired by SonoSite, now FujiFilm SonoSite), and Trillium Therapeutics (NASDAQ: TRIL).
Prior to co-founding AllosteRx, Cynthia was a General Partner with a global fund with main offices in Munich and Montreal, where she built a strong international network of senior management, advisors and co-investors. Cynthia adds another nine years of VC experience in the US and Canada, with a Toronto ON based firm. Cynthia is an accomplished academic with a strong scientific background having spent an additional ten years in R&D in research institutes and life science firms.
Cynthia earned her MBA with first class honors from Rotman School of Management at the University of Toronto and earned her PhD in Molecular Biology with Dean’s honors from McGill University.